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Abstract: Glucoregulatory diseases, such as type 2 diabetes are currently a key public health 
priority. Public health messages have started to include the addition of water in their dietary 
guidelines. Such guidelines however are not based on causal evidence pertaining to the health 
effects of increased water intake, but rather more heavily based upon non-causal or mechanistic 
data. One line of thinking linking fluid intake and health is that hypohydration induces elevated 
blood concentrations of arginine vasopressin (AVP). Research in the 1970s and 1980s implicated 
AVP in glucoregulation, supported by observational evidence. This important area of research 
subsequently appeared to stop until the 21st century during which interest in hypertonic saline 
infusion studies, animal AVP receptor knockout models, dietary and genetic associations, and 
human interventions manipulating hydration status have resurged. This narrative review briefly 
describes and critically evaluates the usefulness of the current AVP-glucoregulatory research. We 
offer suggestions on how to test the independent glucoregulatory effects of body water changes 
compared to elevated circulating AVP concentrations, such as investigating hydration 
manipulations using 3,4-Methylenedioxymethamphetamine. Whilst much research is still needed 
before making firm conclusions, the current evidence suggests that although AVP may be partially 
implicated in glucoregulation, more ecologically valid models using human participants suggests 
this effect might be independent of the hydration status. The key implication of this hypothesis if 
confirmed in future research is that manipulating the hydration status to reduce circulating AVP 
concentrations may not be an effective method to improve glucoregulatory health. 
Keywords: vasopressin; copeptin; hydration; health; metabolism; glycaemia; type 2 diabetes; 
diabetes insipidus; syndrome of inappropriate anti-diuretic secretion; MDMA 
 
1. Introduction 
Historically, research in hydration focused on large deviations in hydration status. Specifically, 
the ill-effects of severe hypohydration in soldiers under extreme conditions were investigated, 
resulting in guidelines for optimal sports performance [1]. Following this, public health guidelines 
started to incorporate hydration recommendations; a more detailed description of this shift has been 
reviewed previously [1]. Briefly, such recommendations may have oversimplified the complex 
relationship between fluid intake and health. One of the most prominent examples is the Institute of 
Medicine guidelines which noted that serum osmolality stays within a well-defined range across a 
multitude of fluid intakes; subsequent guidelines were therefore based on median intakes of self-
reported fluid ingestion (‘adequate intake’) [2]. Thus, to date, fluid intake guidelines have not been 
based on evidence pertaining to improved health, such as lower risk of glucoregulatory diseases (e.g., 
type 2 diabetes [T2D]). 
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Understanding the true causal role of hydration status in health and disease is important in order 
that guidelines are based on the best possible evidence. Increasing fluid intake (particularly from 
water) as a means to manipulate hydration status (and therefore potentially health) represents a low 
cost and easy to understand intervention. Further, the addition of water to the diet does not remove 
hedonically rewarding foods or beverages, the removal of which may contribute to poor adherence 
when implementing a dietary intervention, though more research is certainly warranted to 
understand adherence to recommendations surrounding increasing fluid intake. 
One key mechanism linking hydration status to glucoregulatory health is arginine vasopressin 
(AVP) which is a hormone implicated in body water regulation. This hormone is typically known for 
its impacts on blood pressure regulation, whereby hypohydration (as detected by a 1–2% increase in 
serum osmolality) is met by an increase in circulating AVP [3]. The result of this is V2 receptor binding 
in the collecting ducts of the kidney, signalling an increase in aquaporin expression and redistribution 
to the luminal membrane [4]. This increases water reabsorption, attenuating a reduction in blood 
volume when water intake is low [5]. However, it is important to acknowledge that many factors can 
alter circulating AVP concentrations, including genetics [6], ambient temperature [7], circadian 
rhythms [8], pharmaceuticals [9], recent fluid intake [10], and stress [11]. Thus, the pathway from low 
fluid intake to high circulating AVP to poor glucoregulatory health is difficult to examine as the high 
AVP may be due to other extraneous variables. 
Nonetheless, high plasma concentrations of AVP have been associated with poorer 
cardiometabolic and glucoregulatory health [12,13]. Water intake almost immediately reduces 
plasma copeptin concentrations (a surrogate marker of AVP [14]) for >4 h. This has led some to 
hypothesise that interventions to reduce copeptin via increasing fluid intake may facilitate positive 
health outcomes (e.g., [1,10]). This line of thinking may, however, oversimplify the relationship 
between hydration, AVP, and health. The aim of this narrative review is to briefly discuss early and 
current human research in hydration, AVP, and glucoregulatory health and provide a critical 
perspective as to how to advance the field, focusing on uncoupling the effects of hydration status and 
AVP. 
2. History 
A summary of the studies discussed herein can be found in Table 1. Much research investigating 
the role of AVP in water balance was conducted in the 1970s (e.g., [15,16]) subsequently resulting in 
data suggesting AVP may be linked to glucoregulation. In 1979, Zerbe et al. [17] found elevated 
plasma AVP concentrations in patients with uncontrolled diabetes mellitus (i.e., hyperglycaemia). 
This seemed counterintuitive as hyperglycaemia is typically accompanied by polyuria, which acts to 
help maintain euglycaemia. Rather, these patients had severe hypovolemia sufficient enough to 
induce AVP secretion. It therefore appeared that hyperglycaemia caused polyuria, resulting in 
hypovolemia [17]. Consequently, plasma AVP concentrations increased to counteract the loss in 
blood volume, which may have been potentiated by the osmotic effect of high blood glucose 
concentrations [17]. When treated with insulin (and hydrated), plasma AVP concentration reduced 
by up to five-fold, along with concomitant reductions in plasma osmolality [17]. Such findings were 
key in introducing the idea that AVP may have a role in glucoregulation. 
Nutrients 2019, 11, 1201 3 of 19 
 
Table 1. Literature pertaining to hydration and glucoregulation. 
Author, 
Year 
Study Design Participants Method/Assessment of HYPO Level of HYPO Achieved 
Glucoregulatory 
Assessment 
Findings 
OBSERVATIONAL STUDIES 
Zerbe et al., 
1979 [17] 
Cross-
sectional 
n = 15 men, 13 
women with 
uncontrolled 
diabetes 
AVP concentrations N/A Disease status 
↑ AVP associated with 
poor gluco-regulation 
Enhorning 
et al., 2010 
[12] 
Cross-
sectional and 
longitudinal 
n = 1418 healthy, 
364 IFG, 205 T2D 
men, 2284 
healthy, 311 IFG, 
160 T2D women 
Copeptin concentrations N/A T2D risk 
Cross-sectional: ↑ 
copeptin associated with 
↑ T2D prevalence and IR 
Longitudinal: ↑ copeptin 
associated with ↑ T2D 
(healthy at baseline OR 
Q1 vs. Q4 2.64; IFG at 
baseline OR Q1 vs. Q4 
3.48) 
Roussel et 
al., 2011 [18] 
Longitudinal 
n = 1707 healthy 
men, 1908 healthy 
women 
Plain water intake N/A 
Risk of new-onset 
hyperglycaemia 
↑ Water intake associated 
with ↓ risk of 
hyperglycaemia (<0.5 vs. 
<1.0 and >1.0 L/d OR 
0.68–0.79) 
Pan et al., 
2012 [19] 
Longitudinal 
n = 82,902 healthy 
women 
Plain water intake N/A T2D risk 
× <1 vs. categories up to 
≥6 cups/d RR 0.93–1.09 
Carroll et 
al., 2015 [20] 
Cross-
sectional 
n = 60 healthy 
men, 78 healthy 
women 
Plain water intake N/A T2D risk score 
↑ 1 cup water/d 
associated with 0.72 ↓ 
T2D risk score 
Carroll et 
al., 2016 [21] 
Cross-
sectional 
n = 456 healthy 
men, 579 health 
women 
Plain water intake N/A HbA1c 
Men: ↑ 1 cup water/d 
associated with ↓ 0.04% 
HbA1c 
Women: ↑ 1 cup/d 
associated with × HbA1c 
INFUSION STUDIES 
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Spruce et al., 
1985 [22] 
Randomised 
crossover trial 
n = 6 healthy men 
IV low then high dose AVP vs. 
(isotonic?) IV saline 
↑ AVP by ≥15 pmol∙L−1 Fasted glucose kinetics 
↑ Arterialised venous 
blood glucose 
concentration (low dose 
AVP Δ ~0.3, high dose Δ 
~0.8 mmol∙L−1) 
× insulin concentration 
↑ glucagon concentration 
(Δ ~41 pg∙L−1) 
Keller et al., 
2003 [23] 
Randomised 
crossover trial 
n = 10 healthy 
men 
HypoOsm: IV 4 μg desmopressin + 
200 mL/h water → IV 4 μg 
desmopressin + IV mL/h 0.4% 
saline; vs. HyperOsm: IV 1 mL/kg/h 
2% saline → IV 200 mL/h 5%; vs. 
IsoOsm: ad libitum water ingestion 
HypoOsm: ↓ Posm ~ 21 
mOsm/kg; ↑ body mass 
(~1.6 kg); ↑ urine output 
(~1.6 L) 
HyperOsm: ↑ Posm ~ 13 
mOsm/kg; × body mass or 
urine output 
IsoOsm: × Posm, body mass 
Fasting glucose 
concentrations and 
hyperinsulinaemic-
euglycaemic clamping 
↑ Glucose concentration 
after HyperOsm (5.1 
mmol∙L−1) vs. HypoOsm 
(4.7 mmol∙L−1) vs. IsoOsm 
(4.9 mmol∙L−1) 
↓ Insulin concentration 
HypoOsm vs. IsoOsm 
and HyperOsm 
↑ Endogenous glucose 
appearance during 
HyperOsm vs. IsoOsm 
and HypoOsm 
Jansen et al., 
2018 
[abstract 
only] [24] 
Randomised 
crossover trial 
n = 30 healthy 
men 
HyperOsm: IV 3.0% saline vs. 
IsoOsm: IV 0.9% saline 
HyperOsm: ↑ Posm ~ 18 
mOsm/kg 
IsoOsm: ↑ Posm ~ 3 
mOsm/kg 
OGTT gluco-regulatory 
profile 
↑ Glucose concentration 
at 60 (157 vs. 145 
mg∙dL−1) and 90 (139 vs. 
128 mg∙dL−1) min 
HyperOsm vs. IsoOsm 
WATER INTAKE MANIPULATION STUDIES 
Burge et al., 
2001 [25] 
Controlled 
before-and-
after study 
n = 10 men, 5 
women with T1D 
during insulin 
withdrawal 
Control (euhydrated) phase 
followed by fluid restriction (750 
mL/d) + oral 5 mg metolazone + IV 
40–120 mg furosemide 
↓ Body mass (4.1%); ↓ body 
water% (~3%) 
Fasted insulin 
withdrawn gluco-
regulatory profile (5 h) 
↑ Glucose (6.00 vs. 5.88 
mmol∙L−1), glucagon (66 
vs. 58 ng∙L−1), cortisol 
(497 vs. 384 nmol∙L−1) 
concentrations HYPO vs. 
control phase 
× Insulin concentration 
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↓ Glucosuria (13.9 vs. 27.6 
g) HYPO vs. control 
phase 
Carroll et 
al., 2016 [26] 
Pilot 
randomised 
crossover trial 
n = 4 healthy men, 
1 healthy woman 
HYPO: 45 min sauna + fluid 
restriction (≤200 mL water between 
sauna and testing) 
Control (euhydration): 45 min 
sauna + ≥ 150% sweat losses in 
water between sauna and testing 
↓ Body mass (~1.3%), ↑ 
urine osmolality (↑ ~463 
mOsm/kg vs. control) 
Fasted and OGTT 
glucose and lactate 
concentrations 
↑ Glucose concentrations 
at 45 (5.88 vs. 4.74 
mmol∙L−1) and 60 (4.87 vs. 
4.09 mmol∙L−1) HYPO vs. 
control 
↑ Glucose iAUC (72.9 vs. 
66.6 mmol × 120 min∙L−1) 
HYPO vs. control 
× Lactate concentration 
Johnson et 
al., 2017 [27] 
Randomised 
crossover trial 
n = 9 men with 
T2D during 
medication 
withdrawal 
HYPO: 24–72 h pre-trial, 1 L/d + 
medication withdrawal → 24 h pre-
trial, 0.5 L water + medication 
withdrawal 
Control (euhydration): 72 h pre-trial 
3 L/d water + medication 
withdrawal 
↓ Body mass (1.5%), ↑ urine 
specific gravity (~0.018), 
urine osmolality (~482 
mOsm/kg), Posm (~10 
mOsm/kg), serum sodium 
(~3 mEq/L) HYPO vs. 
control 
Fasted and OGTT 
gluco-regulatory profile 
× Fasted glucose, insulin, 
cortisol, plasma renin 
activity, aldosterone 
concentrations 
↑ Postprandial glucose 
concentration HYPO vs. 
control (AUC 1822 vs. 
1689 mmol∙L−1∙min−1) 
× Postprandial insulin, 
plasma renin activity, or 
aldosterone 
concentrations 
↓ Postprandial cortisol 
concentration control vs. 
HYPO (interaction p = 
0.017, but no differences 
between time points) 
Enhorning 
et al., 2019 
[10] 
Randomised 
crossover trial 
n = 9 healthy men, 
28 healthy women 
(i) Acute 1 L (vs. 10 mL) water 
intake and copeptin 
(ii) 1 week 3 L/d added water intake 
and copeptin vs. control (habitual 
intake) 
N/A 
Fasted and OGTT 
gluco-regulatory profile 
Acute: × glucose or 
insulin concentrations 
during OGTT but ↓ 
glucagon concentration 
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1 week intervention: × 
fasted glucose, insulin, 
glucagon concentrations 
Carroll et 
al., 2019 [11] 
Randomised 
crossover trial 
n = 8 healthy men, 
8 healthy women 
HYPO: 1 h heat tent + 3 mL/kg 
body mass/~34 h water 
Control (euhydration): 1 h heat tent 
+ 150% sweat losses + 40 mL/kg 
lean body mass in water 
↓ Body mass (1.9%), CSMA 
(365 mm2), muscle water 
(~11.1 g/kg vs. control), ↑ 
urine specific gravity 
(~0.010), urine osmolality 
(~442 mOsm/kg), serum 
osmolality (9 mOsm/kg), 
copeptin (14.32 pmol∙L−1) 
× In above after control 
condition 
Fasted and OGTT 
gluco-regulatory profile 
× Fasted or postprandial 
glucose, insulin, ACTH, 
or cortisol concentrations 
HYPO vs. control 
Abbreviations and symbols: Δ, change; ×, no change/no difference; ~, approximately; ↓, decreased; ↑, increased; →, followed by; ACTH, adrenocorticotropic hormone; 
AUC, area under curve; AVP, arginine vasopressin; CSMA, cross-sectional muscle area; d, day; HbA1c, glycated haemoglobin; HYPO, hypohydration; HyperOsm, 
hyperosmolality trial arm; HypoOsm, hypoosmolality trial arm; iAUC, incremental area under the curve; IFG, impaired fasting glucose; IR, insulin resistance; IsoOsm, 
isoosmolality trial arm; IV, intravenous infusion; OGTT, oral glucose tolerance test; OR, odds ratio; Posm, plasma osmolality; Q, quartile; RR, relative risk; T1D, type 1 
diabetes; T2D, type 2 diabetes; vs., versus. 
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Following this, in 1985, Spruce et al. [22] advanced this research, along with theory from research 
in rodents and dogs (e.g., [28,29]), by infusing AVP into healthy adults and measuring 
glucoregulation (including glucose kinetics using labelled glucose). Plasma concentrations of AVP 
reached 22.3 ± 5.4 pmol∙L−1 during a 30 min low dose infusion (25 pmol∙min−1), and 112.3 ± 18.4 
pmol∙L−1 during a subsequent 60 min high dose infusion (75 pmol∙min−1), without altering plasma 
osmolality. Arterialised-venous blood glucose concentrations increased from 4.9 ± 0.1 mmol∙L−1 to 5.2 
± 0.2 mmol∙L−1 after the low dose infusion and to 5.7 ± 0.2 mmol∙L−1 after the high dose. Such changes 
were not found after saline infusion (though no details were given regarding the saline so it is 
assumed that this was isotonic). No effects from any treatment were found for plasma insulin 
concentrations, though plasma glucagon concentrations were ~41 pg∙L−1 higher during the low dose 
AVP infusion, which remained throughout the high dose infusion. 
Such studies offered insights into potential mechanisms by which AVP might be implicated in 
glucoregulatory health. Firstly, as can be seen from the work of Zerbe et al. [17], there is a complex 
interplay between hyperglycaemia and AVP, potentially mediated by hypovolemia induced by 
glucosuria. Although the study was unable to determine the temporal direction of the 
hyperglycaemia-AVP relationship, considering the elevated AVP was accounted for by hypovolemia, 
it is likely that the hyperglycaemia drove higher AVP, rather than vice versa (Figure 1). The AVP-
induced hyperglycaemia may have also created an osmotic stimulus further stimulating AVP 
secretion (Figure 1). 
 
Figure 1. The relationship between diabetes and increased arginine vasopressin, as per the findings 
of Zerbe et al. (1979) [17]. Dotted lines represent a feedback loop, which aims to maintain homeostasis. 
Dashed line represents a theoretical pathway whereby hyperglycaemia induces an osmotic stimulus 
for greater AVP secretion. 
Secondly, Spruce et al. [22] demonstrated an increase in glucose production but not disposal at 
supraphysiological circulating AVP concentrations; this was likely driven by glycogenolysis, rather 
than gluconeogenesis, as there were no changes in gluconeogenic precursors such as lactate. The 
increase in glycaemia was therefore likely due to the greater plasma glucagon concentrations during 
AVP infusion. The divergence in mechanistic findings of these two studies provides a strong rationale 
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to separate patients with diseases from healthy participants when making comparisons between 
theories and studies. 
Beyond the direct role of AVP on glucoregulation, theoretical implications have also been 
hypothesised involving the hypothalamic-pituitary-adrenal (HPA) axis, which were highlighted in 
the 1980s. The HPA axis is implicated in the stress response which can increase hepatic glucose 
output. Upon experiencing stress, AVP and corticotropin-releasing factor (CRF) are synthesised and 
secreted by the hypothalamus. These hormones regulate adrenocorticotropic hormone (ACTH) 
secretion from the pituitary gland, resulting in cortisol secretion from the adrenal cortex. In the 1980s, 
there was sufficient evidence, primarily from animal models, regarding the role of AVP in this 
response [30]. Specifically, during physical stress, CRF (a precursor to ACTH) is produced. In vivo, 
AVP can potentiate the effect of CRF on ACTH production. As AVP is elevated during physical stress, 
there remains a clear pathway between AVP and the stress response, via CRF, ACTH, and ultimately 
cortisol secretion [30]. Accordingly, it may be that increasing water intake to reduce AVP could 
mitigate excessive cortisol secretion, thus reducing hepatic glucose output (Figure 2). 
 
Figure 2. Theoretical relationship between hydration status, arginine vasopressin, and the 
hypothalamic-pituitary-adrenal axis. Dashed lines represent a mediating relationship (i.e., hydration 
status directly influences arginine vasopressin, and hydration status may influence stress); dotted 
lines represent a moderating relationship (i.e., arginine vasopressin determines the propensity of 
corticotropin releasing factor to be cleaved into adrenocorticotropic hormone). 
3. Current Research 
As discussed in the previous section, the studies conducted in the 1970s and 1980s provided 
fascinating insights into the role of hydration and AVP in glucoregulatory health. Yet, despite the 
broad ranging implications of the work, interest in AVP waned until the 2000s. Recently, research 
has expanded the early work and helped provide some critical perspective. 
Water intake can be used as a crude proxy for hydration status. Few studies have investigated 
the relationship between water intake and markers of glucoregulatory health. In a French cohort of 
men and women, higher water intake (assessed via self-reported categories of litres of plain water 
per day) was associated with lower risk of hyperglycaemia [18]. This relationship was replicated in a 
small UK sample of men and women [20] but not in a sample of US female nurses [19] (both of which 
assessed water intake using a food frequency questionnaire). Following these studies, a 
representative UK sample also found an inverse relationship between plain water intake (from four-
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day unweighed diet diaries) and glucoregulatory health, though upon further analysis, this 
association was only found in men [21]. This latest study may explain the null relationship found in 
US nurses [19] due to the sample being exclusively women, compared to the other studies which used 
mixed sex samples. Regarding AVP, this could make sense due to fluctuations in the osmolality set-
point for AVP secretion during the menstrual cycle [31], which may cloud any associations. 
Alternatively, the unvalidated methods of fluid intake may not have accurately captured true water 
intake, explaining the mixed findings. 
Further observational evidence has more directly implicated AVP in glucoregulatory health. In 
a Swedish sample, higher plasma copeptin (as a surrogate marker of AVP) concentrations were 
associated with higher prevalence of T2D and insulin resistance, both cross-sectionally and 
longitudinally [12]. Advancing these associations are studies investigating variations in AVP receptor 
genes. Participants with the variation in the AVP1a receptor gene (specifically, rs1042615 T allele) 
had a higher prevalence of T2D in those with a high fat diet or with overweight [32]; similarly AVP1b 
receptor genes were tentatively associated with increased T2D risk [33]. 
Of course, observational evidence has limited causal inference due to well-known problems such 
as reverse causality and residual confounding. Particularly in the case of water intake, beyond issues 
surrounding misreporting, water intake is part of a cluster of other healthful behaviours such as 
higher fibre intake [34], which may confound any associations. In the case of the genetic observations, 
these could be chance associations, or AVP receptor genes may be collinear with other genes, which 
directly cause disease, thus representing a marker of a different mechanistic process. Nonetheless, 
the genetic work shows some agreement with rodent models, which have used knockout models, 
improving the confidence in these findings [35]. Alternatively, as the outcome for these studies was 
related to glucoregulatory health, there may have been confounding from unmeasured hypovolemia, 
in line with the work of Zerbe et al. in those with uncontrolled diabetes mellitus [17]. In other words, 
the findings may not be due to changes in hydration status or AVP per se, but rather represent a 
response (symptom) to poor glucoregulatory health resulting in glucosuria; AVP then responded to 
maintain blood volume in response to excessive urinary water losses. 
Following these studies, interest has started to focus on understanding the causal relationship 
between hydration status, AVP, and glucoregulation. One study has investigated the acute and 
medium-term effects of water ingestion on glucoregulation. In this study, participants consumed one 
litre of water, after which their copeptin reduced within 30 min and remained suppressed by ~39% 
throughout the full test period of 4 h [10]. Furthermore, after one week of increased water ingestion, 
copeptin was reduced by 15% compared to a control week [10]. This study further split participants 
into ‘responders’ (i.e., copeptin reduced significantly after water ingestion; typically those with 
habitually low water intake, high copeptin and elevated urine osmolality) and ‘non-responders’ (i.e., 
water ingestion did not meaningfully impact their copeptin; typically those with habitually higher 
water intakes and low copeptin) [10]. In ‘responders’, increasing water intake did not result in 
changes in plasma glucose or insulin concentrations, but glucagon concentrations did reduce. Such 
work builds on that of the AVP infusion study [22], by demonstrating a reverse effect. In other words, 
AVP infusion [22] induced higher glucagon concentrations, whereas water intake prescription [10] 
induced lower glucagon concentrations by reducing AVP concentrations (via increasing fluid intake). 
Taken together, there appears to be a dose-dependent effect of AVP on circulating glucagon 
concentrations with mixed findings on whether this impacts glycaemia. 
Arginine vasopressin secretion can be induced by small increases in serum osmolality [15]. 
Accordingly, some studies have investigated the role of hypertonic saline infusion on 
glucoregulation. After hypertonic saline and desmopressin infusion plus fluid restriction in healthy 
adults, Keller et al. [23] found higher fasted plasma glucose concentrations, coupled with an increase 
in endogenous glucose appearance, compared to an iso- and hypo-osmotic trial arm. Similarly, 
hypertonic saline infusion before an oral glucose tolerance test (OGTT) resulted in higher 
postprandial glucose concentrations 60 and 90 min post-glucose ingestion [24]. It is unclear from 
these studies whether the effect seen was directly due to the saline, or indirectly due to 
hyperosmolality-induced AVP secretion (or another as yet unknown mechanism). 
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In terms of the glucoregulatory impacts of direct manipulations to hydration status, there is 
limited current evidence and no replication studies. In 2001, Burge et al. [25] withdrew insulin in 
male and female patients (n = 10) with type 1 diabetes (T1D) and hypohydrated them via fluid 
restriction (750 mL per 24 h) and both oral and intravenous diuretics, losing on average ~4.1% of their 
body mass compared to a euhydrated control arm. Eight h after a set meal, insulin was withdrawn 
and biochemistry was measured for five h. Hypohydration resulted in an elevated glycaemic 
response compared to the control arm [25]. In a subgroup of participants, hypohydration was found 
to result in lower glucosuria compared to the control arm by an amount concordant with the 
difference in glycaemia between the two trial arms. Beyond glucosuria, compared to the euhydrated 
control arm, hypohydration induced higher plasma glucagon and cortisol concentrations, which may 
also explain the higher glycaemia found. 
Similarly, Johnson et al. [27] hypohydrated medication-withdrawn men (n = 9) with T2D (~1.6% 
body mass loss) via fluid restriction, reporting elevated postprandial serum glucose concentrations 
with hypohydration. No differences in plasma insulin were found between trial arms. 
Mechanistically, there was no difference in the renin-angiotensin-aldosterone system (RAAS) 
according to hydration status, but the authors were unfortunately unable to measure AVP. 
Nonetheless, plasma cortisol concentrations were lower 45 min post-glucose ingestion during the 
euhydration trial arm [27]. However, whilst there were main effects and interaction effects, no post-
hoc differences were found between the trial arms. Additionally, the time course of change in cortisol 
concentration does not clearly correspond to that of the glycaemic response. Thus, it may be that there 
is an interaction between hydration status and nutritional status, which mediated a cortisol response, 
rather than cortisol playing a role in hydration-induced alterations in glucoregulation. Alternatively, 
the cortisol trend may be a response to the medication withdrawal, since it is similar (though with a 
more rapid onset) to the work in insulin-withdrawn participants with T1D [25]. Unfortunately, the 
authors did not measure glucosuria for comparison with those with T1D [25]. 
Considering that early work suggested differential mechanisms between those with glucose 
dysregulation [17] and those who are healthy [22], we conducted a pilot study in healthy adults. In 
this study, we hypohydrated participants using a sauna and fluid restriction protocol and 
subsequently conducted an OGTT [26]. As per the research in people with diabetes, we also found a 
higher glycaemic response during hypohydration compared to euhydration. The difference in 
glycaemia emerged after 30 min (slightly earlier than those with T2D [27]). As per the AVP-infusion 
study by Spruce et al. [22] we also did not find a difference in lactate in our pilot work [26], though it 
tended to be higher during hypohydration 60 min post-glucose ingestion. However, this pilot study 
lacked rigorous control (e.g., verbal compliance only for the 24 h pre-trial standardisation), had a 
small sample (n = 5), and was unable to measure mechanisms. The consistency and clarity in the 
results seemed somewhat incredible, thus warranting a tightly controlled follow-up study. 
Therefore, our follow-up study used much more rigorous pre-trial standardisation (four days of 
food, fluid, and physical activity replication) and measured a multitude of mechanisms [11]. In this 
study, participants lost ~1.9% body mass during hypohydration, serum osmolality increased by ~9 
mOsm·kg−1, and their plasma copeptin concentrations increased from levels typically seen in healthy 
adults to levels seen in those with diabetic ketoacidosis [36]. Thus, we are confident that we induced 
meaningful changes in both water balance and AVP concentrations. 
Despite this, we did not find a difference between trial arms in the arterialised-venous serum 
concentrations of glucose or insulin (neither fasted, nor postprandial) [11]. At 45 and 60 min post-
glucose ingestion, there was a small divergence between the trials, similar to our pilot study [26], 
though these data were non-significant and non-meaningful (unlike our pilot). Importantly, there 
were no differences in fasting or postprandial ACTH or cortisol concentrations, contrary to 
participants with T1D [25] and T2D [27]. This may suggest that the interaction between hydration 
status and cortisol responds differentially during medication withdrawal in diabetes compared to 
healthy adults. Additionally, as our results in healthy adults are divergent to those in diabetes, it 
seems likely that glucosuria during euhydration provides a better explanation of the lower glycaemic 
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responses in participants with diabetes. This has been suggested to be tested via comparing those 
with diabetes during medication withdrawal and prescription [11]. 
4. Current and Critical Perspectives and Future Research 
Current rhetoric surrounding hydration is such that the addition of fluids, primarily water, in 
the diet is good for health. This brief narrative review focuses on glucoregulatory health, which has 
links to overall metabolic health and disease (such as T2D). It should be noted that the perspectives 
herein are solely related to the addition of fluids to improve hydration status (i.e., not substitution of 
energy containing beverages) and the impact on glucoregulatory health; other outcomes or contexts 
may be altered differentially and therefore may not be applicable to the perspectives presented. For 
example, growing evidence suggests higher fluid intake to reduce the concentration of urine may aid 
in kidney health [37] or reduce the risk of urinary tract infection recurrence [38], and that hydration 
status may influence endocrine responses to exercise [39]. 
This section therefore aims to: Critically discuss the differences found between participants who 
are healthy and who have diabetes; critically evaluate the role of the HPA axis in hypohydration-
mediated AVP secretion; clarify the purpose of interventions that claim to manipulate hydration 
status (e.g., reduce urine concentration versus increase body water); and provide suggestions for 
future research directions, including methods to uncouple the effects of manipulating hydration 
status (i.e., body water) and circulating AVP concentrations. As it stands, there appears to be limited 
evidence that hydration status directly alters glucoregulation, particularly in healthy adults. 
Replicating the current limited research should therefore be a priority. In those with diabetes, the 
evidence is clearer (though still only two studies [25,27]) but is likely an artefact of glucosuria after 
euhydration since such effects have only been testing during medication withdrawal. Certainly the 
glucosuria hypothesis needs to be further examined. 
As previously mentioned, direct comparisons between healthy participants and those with 
diabetes should be made with caution. Of particular interest is the differential postprandial cortisol 
response found when comparing healthy participants [11] to those with diabetes during medication 
withdrawal [25,27]. Mechanisms for this interaction are as yet poorly understood but they are 
unlikely mediated by AVP or the RAAS. The reason these two mechanisms are unlikely is because: 
(i) The RAAS was not different between hypohydration and euhydration in participants with T2D 
[27]; (ii) AVP concentrations (measured by copeptin) appear to remain elevated at roughly a constant 
magnitude throughout an OGTT [11], though it is unknown if this is the case in diabetes. Thus, this 
change in cortisol is more likely to be mediated via other pathways and may be part of a complex 
interaction related to medication withdrawal and perhaps nutritional status. 
A key underlying theory is that AVP acts along the stress response; thus if an individual is 
hypohydrated during stress, higher AVP will result in higher ACTH (due to AVP potentiating the 
effects of CRH). Ergo, in theory, maintaining low circulating AVP concentrations would result in 
lower CRH cleavage into ACTH, mitigating cortisol-mediated hepatic glucose output (Figure 2). This 
pathway was determined primarily from theory and animal models. We, however, found no 
evidence that hydration status induced a difference in ACTH or cortisol concentrations, despite 
meaningful elevations in copeptin concentrations, even under physical stress (i.e., muscle biopsies) 
[11]. In healthy adults, a large degree (~5% body mass loss) might be needed to induce an elevation 
in fasting circulating cortisol concentrations [39], which is not representative of daily fluctuations in 
the water balance. At a more typical level of body mass loss (~2.5%) no differences were found in 
cortisol concentrations [39], in accordance with our data [11]. Such differences between 2.5% and 5% 
hypohydration may help explain why the high dose AVP infusion caused higher plasma glucose 
compared to the low dose in previous work (18). Thus, if AVP does potentiate the effects of CRF, this 
is unlikely via hydration-mediated AVP changes, at least during every day fluctuations in water 
balance. 
If we therefore examine the totality of evidence critically, one of the conclusions that could be 
made is that AVP is maybe only partially implicated in glucoregulation, however this is perhaps 
independent of hydration status. In other words, our hypothesis is that the physiological effects of 
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hypohydration-induced AVP secretion counter-regulate AVP-induced hyperglycaemia, or the effects 
of increased AVP from other (non-hydration related) causes interact to cause hyperglycaemia, similar 
to the potential interaction between nutritional status and cortisol secretion found in those with T2D 
[27]. Alternatively, it could be that there is a residual factor, as yet unknown, that influences both 
AVP and glucoregulation that is context-specific, thereby explaining why there appears to be no 
direct effect of hypohydration on glucoregulation, whereas there does appear to be an effect of AVP 
infusion. Thus, we propose that there are potentially differences in the physiological responses to 
hydration status that alter glucoregulation, according to whether the response is exogenous (e.g., 
infusion of AVP), or endogenous (e.g., restricting fluid to raise circulating AVP). 
Therefore, we hypothesise that manipulating hydration status in order to reduce AVP is likely 
to have minimal, if any effect, on glucoregulation, at least in healthy populations. This has somewhat 
been demonstrated in the aforementioned one week water intervention (+3 L∙day−1 added to habitual 
intake) [10]. Responders to the intervention had a reduction in fasting plasma glucagon 
concentrations, but not glucose or insulin concentrations, concordant with the increase in glucagon 
concentrations found during AVP infusion [22]. Such results add credence to the idea that reducing 
AVP (measured by copeptin) fails to alter glucoregulation in otherwise healthy individuals, despite 
increasing glucagon. This perhaps suggests that another counter-regulatory process is occurring to 
mitigate the hyperglycaemic effects of glucagon. Considering studies investigating those with T1D 
[25], healthy adults prescribed high water intake [10], and AVP infusion [22], researchers should 
ensure that glucagon is measured so the effects on primary glucoregulatory hormones can be 
captured. It is unclear mechanistically why glucagon increased in these studies but did not always 
result in higher plasma glucose concentrations. 
Our hypothesis is specific to endogenous AVP production mediated by non-compartment-
specific hypohydration. It has been demonstrated that AVP infusion increases glucose concentrations 
without increasing serum osmolality (i.e., without necessarily altering hydration status per se) [8]. 
Although there has been no replication work to confirm these findings, some studies have shown an 
increase in glycaemia when infusing hypertonic (2–5%) saline (which will likely raise AVP 
concentrations) (12 h hypertonic saline at 1 mL∙kg∙h−1 followed by 3 h at 200 mL∙kg∙h−1 [23]; and 2 h 
hypertonic saline infusion at 0.1 mL∙kg∙h−1 [24]). In the AVP infusion study by Spruce et al. [22] no 
effect on blood glucose concentrations was observed after saline infusion (which did not alter AVP 
concentrations), though details regarding the properties of the infused saline were not given; thus as 
no effect of infusion was found, it is likely they used isotonic saline, concordant with the control 
groups in the studies infusing hypertonic saline [23,24]. It is unclear if AVP was altered in these other 
saline infusion studies [23,24]. 
Discordance between the AVP infusion [22] and hypohydration-induced AVP elevations [11] 
may also be explained by nutritional status, i.e., fasted AVP infusion resulted in greater hepatic 
glucose output (but no change in glucose disposal), whereas in a postprandial state, glucose disposal 
is more pertinent. This perhaps suggests that AVP acts specifically to increase hepatic glucose 
metabolism, which may be more directly influenced by infusion studies that create intracellular 
dehydration. Such intracellular dehydration, particularly in hepatocytes, has been shown to increase 
glucagon secretion and is thus implicated in glucoregulation [40,41] and could help explain the 
aforementioned higher glucagon concentrations. 
Taken together, these findings may point towards AVP being the main factor in glucoregulation, 
rather than increased serum osmolality having independent effects (Figure 3). Alternatively or 
additionally, such studies suggest that both (a) exogenous AVP, and (b) compartmental water 
distribution changes can result in increased glycaemia. Whilst these are important mechanistic 
insights, they are not necessarily valid for every day fluctuations in water balance in humans. Further, 
they may represent a physiological condition present in some people due to other factors such as 
genetic variations (i.e., not hypohydration). 
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Figure 3. Theoretical relationship between AVP or saline infusion and glucoregulation. Dotted line 
with diamond arrowhead represents no effect. Greyed out box means unmeasured, but theoretically 
on the pathway. 
A counter argument to our hypothesis may be differences related to genetic influences [32,33]. 
Although these studies highlight genetic variation relating to AVP (and therefore by inference water 
balance physiology) are correlated to poorer glucoregulatory and metabolic health outcomes, they 
lack causality. Specifically, such genetic variations may be collinear with other genetic variations that 
are detrimental to health. If, for the sake of argument, we assume the association is causal, such 
findings may mean that genetic variation in water balance physiology can cause increased risk of 
cardiometabolic disease. However, this does not automatically mean that altering water balance 
behaviours (i.e., increasing fluid intake) will reduce this genetically determined disease risk. This of 
course should be further investigated as perhaps targeting people with certain variants could increase 
the likelihood that a water intervention might be efficacious (and in the case of the previously 
discussed water-prescription study by Enhorning et al. [10], may explain some variation in the 
responders and non-responders). 
Further considerations should also be taken into account in future research. Firstly, the 
epidemiology investigating water intake and glucoregulatory health is at least suggestive of sex 
differences. Considering that much physiology research is based on men (e.g., [27]), or when women 
are included they are in their (estimated) follicular phase, post-menopausal, or taking hormonal 
contraceptives (e.g., [11]), studies investigating water balance and health outcomes during the luteal 
phase of the menstrual cycle would be of mechanistic interest. The osmolality set point for AVP 
secretion changes throughout the menstrual cycle [31] as does carbohydrate and fat oxidation [42] 
and understanding how these fluctuations influence health would aid in our mechanistic 
understanding of whether and how AVP influences glucoregulatory health. 
Secondly, pre-trial control of known confounding factors should be emphasised. Our recent 
study included four days of pre-trial diet, activity, and fluid intake standardisation using weighed 
food diaries and combined accelerometry and heart rate monitors [11]. Such control to our knowledge 
has not been utilised in previous hydration and health related research. To demonstrate why this 
may be important, comparatively, our pilot work used 24 h of diet and activity standardisation in the 
form of verbal confirmation [26]. The stark differences in the results from these studies may indicate 
that lack of pre-trial standardisation at least partially contributed to divergences in glucoregulation 
during the OGTT. 
Thirdly, another explanation as to why there have been conflicting findings, may be the use of 
venous versus arterialised-venous blood. In our pilot work, we used venous blood and found a large 
difference in the blood glucose response between hydration states [26]. Contrarily, in our follow-up 
study, we used arterialised-venous blood [11]. As arterialised-venous blood more closely represents 
the glucose concentration that cells are exposed to, whereas venous blood more closely represents 
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the glucose the cells have not taken up, it is reasonable to suspect that this may (at least in part) 
explain the differences in our findings [43]. Whilst this is a possibility that warrants further 
investigation, it is worth noting the use of arterialised-venous blood during AVP infusion [22], which 
still demonstrated a difference in glycaemia. This of course may also be due to the use of exogenous 
AVP infusion versus endogenous AVP via dehydration. 
Further adding doubt to the arterialisation theory is that in our study, after the OGTT, we 
measured multiple facets of appetite, including serum glucose and insulin concentrations from (non-
arterialised) venous blood after an ad libitum test meal. During this period of testing, plasma copeptin 
concentrations and serum osmolality remained elevated during hypohydration but blood glucose 
and insulin concentrations remained remarkably similar to the euhydrated trial arm [44]. Whilst the 
ad libitum nature of the test meal confounds any definitive inferences, energy intake was (on average) 
approximately equal between the trial arms, and accordingly, there were no differences in serum 
glucose or insulin concentrations. If arterialisation was a cause of the disparities between studies, it 
may have been apparent during this period of testing. 
A final consideration is the measurement of hydration status and how this relates to the 
conclusions of studies. There is currently no gold standard measure of hydration, as each method has 
its strengths and limitations according to the context. Our recent study, to our knowledge, measured 
hydration status more extensively than any other research investigating hydration and health [11], 
including body mass, plasma copeptin concentration, urine and serum osmolality, urine specific 
gravity, peripheral quantitative computer tomography, muscle biopsies, and fluid intake diaries. 
Whilst this level of measurement is unnecessary for all research, future work should consider the 
appropriateness of the measures taken, and a clear distinction needs to be made before starting the 
trial: Is the aim to alter urine concentration, AVP, or body water? 
If the aim of the study is to increase urine volume or decrease urine concentration, then measures 
such 24-h urine volume, urine osmolality, or urine specific gravity are suitable. However, these 
measures alone do not indicate that hydration status has been altered, though they may be sufficient 
to infer (with caution) that AVP has been manipulated. Changes in these outcomes simply 
demonstrates that the body has no (or at least less) need to reabsorb extra fluid, or fluid has been 
consumed in a way that is conducive to increased/decreased urinary output such as consuming a 
large bolus of fluid rapidly (e.g., Shafiee et al. [45]). 
Equally, measuring AVP (or a marker of) alone does not necessarily infer that body water 
(hydration status) has been altered. Arginine vasopressin is secreted in order to reduce water losses. 
Thus at least in the early phase of elevated concentrations, it should be effective at maintaining water 
balance within the body. Acutely, measuring body mass can be effectively used to determine whether 
body water has been altered, though this implies energy balance, emphasising the importance of 
proper pre-measure standardisation of diet and activity. Therefore, it is essential to specify the aim 
of the study, use the appropriate (combination of) measures, and most importantly to frame 
conclusions within the correct context (i.e., are the inferences based on reducing urine concentration, 
circulating AVP, or manipulating body water)? 
This raises a wider question regarding how we can improve the measurement of hydration 
status and accurately assess the contribution of hydration-mediated changes in AVP on 
glucoregulatory health. We propose two potential pathways that could help uncouple the 
independent effects of alterations in body water and circulating AVP concentrations: (i) Investigating 
3,4-Methylenedioxymethamphetamine (MDMA), and (ii) investigating those with water balance 
conditions, namely the syndrome of inappropriate antidiuretic hormone (another name for AVP) 
secretion (SIADH) and diabetes insipidus. 
3,4-Methylenedioxymethamphetamine is the psychoactive ingredient in the recreational drug 
more commonly known as ‘ecstasy’. In terms of hydration, this drug is most fascinating as it gives 
the symptoms of hypohydration (reduced urine volume, and increased urine osmolality [despite 
greater fluid ingestion], plasma copeptin concentrations, thirst, desire for fluid, dry mouth, and body 
temperature), whilst simultaneously causing cell swelling (due to the elevation of AVP resulting in 
hyponatraemia and greater water retention, as well as the greater fluid ingestion) [36]. Mixed effects 
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have been found for whether plasma osmolality changes from MDMA administration: Two placebo-
controlled studies found no effect [46,47], whereas another natural study taking pre- and post-
clubbing measured in self-administering participants found a post-MDMA reduction in plasma 
osmolality [48], with similar results in another placebo-controlled trial though this study did not find 
an interaction between MDMA and AVP [49]. As studies varied in their levels of control regarding 
fluid intake, physical activity, and dosage, the effects of MDMA on plasma osmolality need to be 
clarified in order to fully understand the hydration-AVP-health interactions (described below). For 
example, if serum osmolality remains unchanged post-MDMA administration, this would provide 
clear evidence for the effects of AVP on glucoregulation, independent of other hydration-related 
factors. 
Accordingly, MDMA could (a) help improve our understanding of hydration physiology and 
measurement, and (b) provide a useful model to help assess the role of AVP in glucoregulatory 
health. With regards to the first point (a), if we were able to find a simple measure of hydration that 
accurately describes those under the influence of MDMA as hyperhydrated, despite the 
overwhelming symptoms of hypohydration, we may more effectively be able to assess hydration 
status. Additionally, such MDMA-induced symptoms have some sex-differences (specifically that 
copeptin concentration increase more in women than men [47]), further highlighting the usefulness 
of an MDMA model in understanding the mechanisms surrounding water balance. An unintended 
consequence of pursuing this line of research may be a reduction in MDMA-related deaths, which 
are primarily caused by hyponatraemia or hyperhydration. 
Regarding the latter point (b), considering MDMA results in both elevated AVP and 
hyperhydration, if AVP was the cause of hyperglycaemia, this should mean MDMA induces 
hyperglycaemia. Of course this is very difficult to test for several reasons, such as ethical and legal 
restrictions, and confounding factors in natural settings such as the temperature and activity patterns 
of users. As such, there is very limited research. In rats, MDMA administration results in 
hypoglycaemia [50]. However, in humans administered MDMA in a natural setting, but with no 
control of food or fluid intake, six out of 21 participants had a non-significant elevation in blood 
glucose concentrations compared to baseline [51]. 
It is unclear as to whether MDMA increases circulating cortisol concentrations or not. In a club 
setting, MDMA increased cortisol [52], whereas in a placebo-controlled setting it did not [46], 
meaning it is unclear as to whether euglycaemia was maintained in MDMA administered in a natural 
setting [51] despite changes in cortisol secretion. It may be concluded from these studies that MDMA-
induced endogenous AVP secretion is at least not associated with glucose dysregulation. Using an 
MDMA model of AVP physiology and glucoregulatory outcomes may be useful in aiding our 
understanding of these complex relationships as it enables us to uncouple the mechanistic effects of 
hydration status and AVP. Nonetheless, caution should still be taken when making inferences from 
such results to the general population as MDMA affects a multitude of metabolic and neuronal 
pathways, which could also be implicated in glucoregulation. However, this does not necessarily 
detract from the mechanistic understanding that such a model can bring. 
Following on from an MDMA model, is investigating effects in those with SIADH. This 
condition is characterised by low serum osmolality (which can be accompanied by cell swelling and 
hyponatraemia), highly concentrated urine, and elevated AVP [53]; thus in some ways this condition 
mimics the water balance effects of MDMA administration [46,48,54] and could also be used as a 
model to uncouple the effects of body water compared to AVP in glucoregulatory health. Conversely, 
neurohypophyseal diabetes insipidus is the underproduction of AVP resulting in excessive fluid 
losses [55] (though there are other forms which can result in elevated AVP, e.g., nephrogenic diabetes 
insipidus [56]). 
We were unable to find data regarding glucoregulatory health in either of these conditions. If 
the AVP-induced hyperglycaemia model were correct, we would expect to see a greater prevalence 
of markers of glucose intolerance (e.g., impaired fasting glucose, or higher T2D prevalence) in those 
with SIADH, and lower prevalence in those with diabetes insipidus. In the absence of clear current 
data, the relationship between diabetes insipidus and mellitus was previously of interest in the early 
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1900s; although there were some cases of increased glucosuria with diabetes insipidus, there was no 
evidence that diabetes mellitus prevalence was different from the general population [57]. 
Epidemiological work could investigate this relationship further in order to discern whether more 
causal work is warranted. As with MDMA research, inferences from both SIADH and diabetes 
insipidus models should be made cautiously when extrapolating to the general population; for 
example, in SIADH, inappropriate secretin secretion is currently the most likely cause of the 
condition, rather than problems with the AVP response per se [58]. Further, the study of those with 
diabetes insipidus may help to uncouple the effects of glucosuria and glucoregulation found in those 
with T1D and T2D during medication withdrawal; this may however, additionally reduce the 
applicability of this model to the general population. Nonetheless, such models provide useful 
mechanistic understandings, which can help drive future hypotheses. 
Future research should also consider longer-term interventions. Whilst this has ethical 
implications, there is ample evidence to suggest that some people are chronic low fluid drinkers; 
understanding the causal implications of this behaviour is essential for public health. Although the 
acute evidence in healthy adults at least suggests that such an intervention will not cause metabolic 
harm, reducing some initial ethical concerns, important questions remain to be answered as to 
whether this lack of harm extends beyond a matter of days. In other words, does chronically high 
AVP induced by low fluid intake eventually fulfill the HPA axis causing elevated cortisol 
(notwithstanding other potential mechanisms such as changes in cell volume which may influence 
glucoregulation [40,41]). 
Finally, much of the mechanistic work relating AVP to glucoregulatory health has involved 
isolating a single mechanism (AVP in the case of the focus of this review, but also hepatocyte volume 
and more recently, adipocyte AVP receptor expression). Such studies are vitally important for 
understanding the underlying physiology and generating testable hypotheses. However, the more 
recent work in humans, which has encompassed the full range of the physiological effects of 
hypohydration, demonstrates that such models are not necessarily applicable to human fluctuations 
in water balance. Thus in order to understand the glucoregulatory impacts of AVP, ecologically valid 
methods should be used in order to make accurate inferences applicable to human health. 
5. Conclusions 
Overall, this narrative review provided a brief account of the history of AVP-glucoregulation 
related research. Whilst the earlier research gave insight into potential mechanisms backed by 
observational studies, tightly controlled studies do not at this time appear to support a causal role for 
hypohydration-induced increases in AVP on glucoregulatory health. Although studies in people 
with diabetes show euhydration results in lower glycaemia, this is likely due to glucosuria from 
medication withdrawal; though more research needs to confirm this. Such findings in their totality 
suggest that AVP may be implicated in glucoregulation particularly at supraphysiological 
concentrations, but possibly not via every day alterations in non-compartment-specific hydration 
status, at least in healthy (young) adults. However, research in this field using ecologically valid 
methods in both healthy participants and those with diabetes is in its infancy. Several ideas for further 
examining mechanisms and outcomes were also discussed, with an emphasis on replication of 
current studies. 
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